The chorus has been growing for months and now it’s official: Americans across the political spectrum agree that prescription prices are too high. The drug industry could hardly have done a better job uniting the country. A new poll from the Kaiser Family Foundation finds that 72 percent of Americans believe drug costs are “unreasonable.” And in a sign of real trouble for the … [Read more...]
Healthcare Providers Comment on 340B Program Proposed Rule
Regulation addresses ceiling price calculation and drugmaker finesAugust 21, 2015—The Health Resources and Services Administration should clarify in a forthcoming 340B program rule that drugmakers must give refunds for all overcharges on 340B drugs above a reasonable dollar amount and within a reasonable amount of time after their discovery, including those due to routine average manufacturer price "true-ups," groups representing healthcare … [Read more...]
OMB Approves 340B Omnibus Guidelines
Milepost passed on the route to publicationAugust 19, 2015—The White House Office of Management and Budget has finished reviewing the proposed 340B program omnibus guidelines, moving them closer to publication for notice and comment in the Federal Register. … [Read more...]
CMS Submits Medicaid Drug Pricing Final Rule to OMB for Review
Last stop before publication for the long-delayed regulation?August 6, 2015—Three and a half years after being released for public comment, the Medicaid covered outpatient drug rule, a.k.a. the AMP (average manufacturer price) final rule, could finally be nearing the finish line. … [Read more...]
OMB Review Extended for 340B Omnibus Guidance
It is unclear how long the extension could lastAugust 5, 2015—The wait for long-awaited 340B program omnibus guidelines just got longer. … [Read more...]
340B Recertification Is Underway for Hospitals
Facilities have five weeks to complete the procedureAugust 5, 2015—Hospitals have from today until Sept. 9 to recertify their eligibility for the 340B drug discount program. … [Read more...]
Monitor Has New Look and Functionality
New design adapts to handheld devicesAugust 5, 2015—The Drug Discount Monitor launched a new responsive webpage design to make reading our articles easier on smartphones and tablets. This is the third major design change for the Monitor, which began as print newsletter in July 2004. The first big change came in early 2009, when we shortened our name updated our print and website appearance. We revised our … [Read more...]